HAEMONETICS CORP — Director's Dealing 2023

May 17, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2023-05-15

Reporting Person: Simon, Christopher (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-05-15	Common Stock	A	18225	—	Acquired	222792	Direct
2023-05-16	Common Stock	F	1586	$89.21	Disposed	221206	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-05-15	Non-qualified Stock Option (Right to Buy)	$89.16	A	41177	Acquired	2030-05-15	Common Stock (41177)	Direct

Footnotes

F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3: This number includes unvested RSUs previously reported.

F4: Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I.

F5: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.